liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D, L-lactic-co-glycolic) acid nanoparticles nanoparticles
University of Calif San Diego, CA 92093 USA.
University of Calif San Diego, CA 92093 USA.
University of Calif San Diego, CA 92093 USA.
University of Calif San Diego, CA 92093 USA.
Show others and affiliations
2015 (English)In: Breast Cancer Research, ISSN 1465-5411, E-ISSN 1465-542X, Vol. 17, no 48Article in journal (Refereed) Published
Abstract [en]

Introduction Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as potent immune adjuvant. Method In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2) positive breast cancer. Results Free peptide did not significantly augment immune responses but, when delivered in poly(D, L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2 specific T cells was observed in vitro. Vaccination of HER2NEU transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91 loaded PLGA-NPs enhanced the activation of HER2 specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusion Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.

Place, publisher, year, edition, pages
BioMed Central , 2015. Vol. 17, no 48
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-117376DOI: 10.1186/s13058-015-0552-9ISI: 000352093600001PubMedID: 25882711OAI: oai:DiVA.org:liu-117376DiVA: diva2:807851
Note

Funding Agencies|US Army Medical Research and Material Command from the National Institutes of Health/NCI [W81XWH-07-1-0412, 5U54CA119335]

Available from: 2015-04-24 Created: 2015-04-24 Last updated: 2017-12-04

Open Access in DiVA

fulltext(686 kB)113 downloads
File information
File name FULLTEXT01.pdfFile size 686 kBChecksum SHA-512
530428537230481f0a17192978b912255f255c9c1300d9b9ff850c126db225370df0fc286ed4a0b8919a2f6d37033c43702264fc6774e70f9da467f32b9fb93b
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Larsson, Marie

Search in DiVA

By author/editor
Larsson, Marie
By organisation
Division of Microbiology and Molecular MedicineFaculty of Health Sciences
In the same journal
Breast Cancer Research
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 113 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 112 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf